547 related articles for article (PubMed ID: 28373215)
1. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
6. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
7. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
Allard B; Allard D; Stagg J
Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
9. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
10. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
11. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
[TBL] [Abstract][Full Text] [Related]
14. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
15. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Tray N; Weber JS; Adams S
Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
[TBL] [Abstract][Full Text] [Related]
16. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
17. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
19. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Mosely SI; Prime JE; Sainson RC; Koopmann JO; Wang DY; Greenawalt DM; Ahdesmaki MJ; Leyland R; Mullins S; Pacelli L; Marcus D; Anderton J; Watkins A; Coates Ulrichsen J; Brohawn P; Higgs BW; McCourt M; Jones H; Harper JA; Morrow M; Valge-Archer V; Stewart R; Dovedi SJ; Wilkinson RW
Cancer Immunol Res; 2017 Jan; 5(1):29-41. PubMed ID: 27923825
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
Bazhin AV; Amedei A; Karakhanova S
Front Immunol; 2018; 9():2878. PubMed ID: 30568661
[No Abstract] [Full Text] [Related]
[Next] [New Search]
